-
ADC Therapeutics Strengthens Team with New Employee Inducement Grants
NYSE: $ADCT ADC Therapeutics SA, a commercial-stage, late-stage biotechnology company focused on the development and commercialization of antibody drug conjugates (ADCs) for patients suffering from cancer, recently announced a significant commitment to its growing workforce. In a filing dated December 17, 2024, the company disclosed the granting of equity awards to newly hired employees under…
-
Anixa Biosciences Advances CAR-T Therapy with U.S. Adopted Name Approval
NASDAQ: $ANIX Anixa Biosciences, Inc., a biotechnology company focused on the development of innovative cancer therapies, has reached a significant milestone in the progression of its CAR-T cell therapy candidate. The company announced that the United States Adopted Names (USAN) Council has approved the non-proprietary name for its novel CAR-T therapy. This approval of a…
-
Edgewise Therapeutics Announces Inducement Grants Under Nasdaq Rules
NASDAQ: $EWTX Edgewise Therapeutics Reports Inducement Grants as Permitted by Nasdaq Listing Rules Edgewise Therapeutics, Inc., a company focused on developing transformative therapies for muscular dystrophies, has recently announced the issuance of new equity awards. These grants were made as inducement awards to newly hired non-executive employees, a practice fully compliant with the Nasdaq Stock…